Norovirus vaccine
US11596680B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 18, 2020 |
| Grant date | Mar 7, 2023 |
| Priority date | — |
| Expiry date | May 18, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/16071
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.